Patents by Inventor Gary Gooch

Gary Gooch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
    Patent number: 8329421
    Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 11, 2012
    Assignee: Ventana Medical Systems, Inc.
    Inventors: William C. Powell, Linda Willoughby Kivi, Patrick C. Roche, Gary Gooch, Fabien Gaire
  • ANTIBODIES SPECIFIC FOR THE C-TERMINAL REGULATORY DOMAIN OF EGFR AND THEIR USE
    Publication number: 20100285025
    Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.
    Type: Application
    Filed: July 11, 2008
    Publication date: November 11, 2010
    Inventors: William C. Powell, Linda Willoughby Kivi, Patrick C. Roche, Gary Gooch, Fabien Gaire
  • EGFR ANTIGEN-BINDING MOLECULES AND USES THEREOF
    Publication number: 20090017050
    Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.
    Type: Application
    Filed: July 11, 2008
    Publication date: January 15, 2009
    Inventors: William C. Powell, Linda Willoughby Kivi, Patrick C. Roche, Gary Gooch, Fabien Gaire